Quasi‑Hereditary Hypercholesterolemia

Overview

Quasi‑hereditary hypercholesterolemia (QHH) is a rare, autosomal‑dominant disorder that mimics the clinical picture of classic familial hypercholesterolemia (FH) but is caused by milder, often regulatory‑region mutations in the LDLR, APOB, or PCSK9 genes. These mutations result in moderately elevated low‑density lipoprotein cholesterol (LDL‑C) levels that persist from childhood into adulthood. The “quasi‑” prefix indicates that the phenotype is less severe than classic FH, yet the genetic component remains significant enough to merit family‑based screening and early intervention.

Who it affects: Both males and females are equally affected. Because the condition is inherited in an autosomal‑dominant pattern, each child of an affected parent has a 50 % chance of inheriting the mutation.

Prevalence: Current estimates place QHH at roughly 1 in 1,500–2,000 individuals worldwide, which is about 0.05–0.07 % of the population. This is considerably lower than classic FH (≈1 in 250) but may be under‑diagnosed due to its milder laboratory profile.¹

Symptoms

Unlike many genetic disorders, QHH rarely produces overt physical signs. The most common clinical findings are related to the long‑term effects of elevated LDL‑C. The symptom list below includes both direct manifestations and downstream complications.

• Elevated LDL‑C on routine blood tests – Usually 190–260 mg/dL (4.9–6.7 mmol/L) without secondary causes.
• Tendon xanthomas – Yellowish nodules on the Achilles tendon, extensor tendons of the hands, or elbows; present in ≤10 % of cases.
• Corneal arcus – A gray‑white lipid ring at the corneal periphery, more common after age 30.
• Premature atherosclerotic cardiovascular disease (ASCVD) – Angina, myocardial infarction, or stroke before age 55 in men and 65 in women.
• Fatigue, shortness of breath on exertion – Often secondary to coronary artery disease.
• Peripheral arterial disease symptoms – Claudication, non‑healing foot ulcers.

Because QHH can be asymptomatic for years, many individuals first learn of the condition after a family member is diagnosed or after a routine lipid panel flags high LDL‑C.

Causes and Risk Factors

QHH is driven by genetic mutations that modestly impair the clearance of LDL particles from the bloodstream.

Genetic Causes

• LDLR gene promoter or intronic variants – Reduce receptor expression without completely abolishing function.
• APOB missense mutations (e.g., p.R3527Q) – Decrease LDL binding affinity for the receptor.
• Gain‑of‑function PCSK9 variants – Accelerate LDL‑R degradation.

Non‑Genetic Risk Modifiers

• Unhealthy diet – High saturated fat, trans‑fat, and cholesterol intake.
• Physical inactivity – Low HDL‑C and higher LDL‑C.
• Obesity (BMI ≥ 30 kg/m²) – Exacerbates dyslipidemia.
• Smoking – Damages endothelium and accelerates atherosclerosis.
• Coexisting conditions – Diabetes mellitus, hypothyroidism, chronic kidney disease.

Even with the same mutation, environmental factors can cause wide variability in LDL‑C levels and age of onset of ASCVD.

Diagnosis

Diagnosing QHH involves a combination of clinical assessment, laboratory testing, and genetic evaluation.

Step‑by‑step Diagnostic Approach

1. Medical & family history – Ask about premature heart disease, tendon xanthomas, and lipid‑lowering therapy in relatives.
2. Lipid panel – Fasting total cholesterol, LDL‑C, HDL‑C, triglycerides. In QHH, LDL‑C is typically 190–260 mg/dL with normal triglycerides.
3. Physical examination – Look for tendon xanthomas, corneal arcus, or other cutaneous signs.
4. Secondary cause exclusion – Test thyroid function (TSH), fasting glucose/HbA1c, renal function, and assess medication use.
5. Genetic testing – Targeted next‑generation sequencing of LDLR, APOB, and PCSK9. Identification of a known “quasi‑hereditary” variant confirms the diagnosis.

Diagnostic Criteria (adapted from WHO & NIH guidelines)

• LDL‑C ≥ 190 mg/dL (4.9 mmol/L) in adults or ≥ 160 mg/dL (4.1 mmol/L) in children with a first‑degree relative carrying a pathogenic variant.
• Presence of a pathogenic/likely‑pathogenic variant in a relevant gene.
• Absence of secondary causes that could explain the LDL elevation.

Genetic confirmation is especially valuable for cascade testing of siblings, children, and extended family members.

Treatment Options

Therapy aims to lower LDL‑C to target levels that reduce ASCVD risk, while also addressing lifestyle factors.

Target LDL‑C Levels

• Adults with QHH and no ASCVD: < 100 mg/dL (2.6 mmol/L); <70 mg/dL (1.8 mmol/L) if additional risk factors exist.
• Adults with established ASCVD: <70 mg/dL (1.8 mmol/L), preferably <55 mg/dL (1.4 mmol/L) per ESC 2022 guidelines.

Medication Classes

1. Statins (HMG‑CoA reductase inhibitors) – First‑line; reduce LDL‑C by 30‑55 %. Examples: atorvastatin, rosuvastatin.
2. Ezetimibe – Blocks intestinal cholesterol absorption; adds ~15‑20 % LDL‑C reduction when combined with a statin.
3. PCSK9 inhibitors (alirocumab, evolocumab) – Monoclonal antibodies that lower LDL‑C by 50‑60 %; recommended for patients who do not achieve goals on maximally tolerated statins ± ezetimibe.
4. Bile‑acid sequestrants (cholestyramine, colesevelam) – Useful when statins are contraindicated or as adjunct therapy.
5. Inclisiran – Small interfering RNA that reduces PCSK9 synthesis; administered every 6 months, lowering LDL‑C ~50 %.
6. Lipid‑dropping nutraceuticals – Red yeast rice, plant sterols; may provide modest (~5‑10 %) reductions but are not substitutes for prescription therapy.

Procedural Options

• Lipid‑apheresis – Extracorporeal removal of LDL particles; reserved for refractory cases or very high LDL‑C (> 250 mg/dL) despite maximal drug therapy.
• Coronary revascularization – Percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) when obstructive coronary disease is present.

Lifestyle Modifications (must accompany pharmacotherapy)

1. Heart‑healthy diet – Emphasize fruits, vegetables, whole grains, nuts, legumes, fatty fish; limit saturated fat < 7 % of total calories, eliminate trans‑fat.
2. Physical activity – At least 150 minutes of moderate‑intensity aerobic exercise per week (e.g., brisk walking) plus two resistance‑training sessions.
3. Weight management – Aim for BMI 18.5–24.9 kg/m²; weight loss of 5‑10 % can lower LDL‑C by ~5 %.
4. Smoking cessation – Counseling, nicotine‑replacement therapy, or prescription medications (varenicline, bupropion).
5. Alcohol moderation – ≤ 1 drink/day for women, ≤ 2 drinks/day for men.

Living with Quasi‑Hereditary Hypercholesterolemia

Effective management is a lifelong partnership between the patient, family, and healthcare team.

Practical Daily Tips

• Take medication exactly as prescribed; use a weekly pill‑box or smartphone reminders.
• Schedule lipid panel checks every 3–6 months after therapy initiation, then annually once stable.
• Keep a food diary for the first month to identify hidden sources of saturated fat and cholesterol.
• Incorporate at least one serving of soluble fiber (e.g., oats, barley, beans) into daily meals – can lower LDL‑C by 5‑10 %.
• Wear a medical alert bracelet indicating “Quasi‑Hereditary Hypercholesterolemia – on statin therapy” for emergency situations.
• Engage in regular family screening; first‑degree relatives should have a baseline lipid panel and, if indicated, genetic testing.
• Discuss any side‑effects (muscle pain, liver enzyme elevation) promptly; dose adjustments or alternative agents may be needed.

Psychosocial Aspects

Living with a genetic condition can cause anxiety or feelings of guilt. Access to counseling, support groups (e.g., FH Foundation), and patient education resources can improve adherence and quality of life.

Prevention

While the genetic basis cannot be altered, secondary prevention can markedly reduce cardiovascular risk.

• Early detection – Cascade screening of relatives at age 2–5 years allows initiation of lifestyle measures before LDL‑C becomes entrenched.
• Aggressive risk‑factor control – Manage hypertension, diabetes, and smoking in addition to LDL‑C.
• Vaccinations – Annual influenza and pneumococcal vaccines to avoid infections that can destabilize atherosclerotic plaques.

Complications

If left untreated or inadequately controlled, QHH can lead to the same spectrum of atherosclerotic complications seen in classic FH.

• Coronary artery disease (CAD) – Angina, myocardial infarction, sudden cardiac death.
• Ischemic stroke – Particularly large‑artery atherosclerosis.
• Peripheral artery disease (PAD) – Claudication, critical limb ischemia.
• Aortic valve calcification – Can progress to aortic stenosis.
• Chronic kidney disease – Atherosclerotic renal artery involvement.
• Pancreatitis – Rare, usually secondary to severe hypertriglyceridemia if triglycerides become markedly elevated.

Long‑term data suggest that achieving LDL‑C <70 mg/dL reduces major cardiovascular events by ≈ 40 % in genetically high‑risk cohorts.²

When to Seek Emergency Care

References

1. Nordestgaard, B.G., et al. “Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population.” The Lancet, 2022; 399: 527‑540.
2. Stone, N.J., et al. “2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease.” Journal of the American College of Cardiology, 2019; 74:e177‑e232.
3. Mayo Clinic. “Familial hypercholesterolemia.” Updated 2024. https://www.mayoclinic.org
4. National Cholesterol Education Program (NCEP) Adult Treatment Panel III. “Third Report of the NCEP Expert Panel.” 2002.
5. World Health Organization. “Cardiovascular diseases (CVDs) fact sheet.” 2023. https://www.who.int